Michael Gibney

feedback. Boston’s home-state biotech hub has seen better days. But there are also reasons to believe a comeback is on the horizon based on last year’s performance, according to industry nonprofit MassBio. MassBio reported gloomy statistics from the Commo... See more

feedback. When billionaire entrepreneur and venture capital investor Sean Parker launched the Parker Institute for Cancer Immunotherapy in 2016, a new wave of oncology medicines was breaking on the shores of the pharma industry. Checkpoint inhibitors like... See more

feedback. Biogen is on a mission to transform — from building a new headquarters in Kendall Square near Boston to further expanding the aperture beyond its multiple sclerosis beginnings — and emerging technologies are set to be key players in that effort.... See more

feedback. Dr. Patrizia Cavazzoni. Dr. Jacqueline Corrigan-Curay. Dr. George Tidmarsh. Dr. Richard Pazdur. Dr. Tracy Beth Høeg. These five doctors have one major thing in common: They have all been director of the Center for Drug Evaluation and Research th... See more

feedback. The year started strong for pharma M&A with Johnson & Johnson inking the largest deal of 2025 in the first two weeks of January. After that, no other matchup reached those heights again. But despite an M&A environment that hasn’t fir... See more